Botulinum Toxin and Pain.
Analgesia
Axonal transport
Botulinum toxin type A
Botulinum toxin type B
CNS
Pain
SNAP25
SNARE
Transsynaptic transport
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
6
2
2020
medline:
22
1
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
This chapter is focused on analgesic mechanism of action of botulinum toxin type A (BoNT-A) including the action beyond peripheral nerve endings. With the exception of the meninges and possibly urinary bladder, the presence of BoNT-A activity in the periphery, cleaving SNAP25 as a target molecule, up to now was not convincingly shown. In contrast many reports demonstrated BoNT-A activity and the presence of cleaved SNAP25 in the brain and spinal cord. In a model of mirror pain BoNT-A analgesic effect can be achieved even without participation of peripheral nerve ending. Thus generalized hypothesis central or peripheral mechanism of action belongs to history, and there is a need to confirm or dispute the results with meninges, urinary bladder, and possibly with other, especially visceral organs.There are two general options for the central actions of BoNT-A: 1. The activity ends by silencing primary sensory neuron thereby stopping the pain information further in the CNS. 2. Or thereafter, indirectly or transsynaptically, BoNT-A triggers smaller or larger neural loops, forming memory of pain in the CNS that could explain the bilateral effects after unilateral peripheral administration, similar effect in mirror image allodynia and the like Intensive research has shown that peripherally administered BoNT-A reaches the CNS by axonal transport. There is increasing evidence that BoNT-A is preventing pain in a growing range of disorders. In the absence of unexpected findings, or an increase in the uncontrolled use of illicit preparations by uneducated persons, BoNT-A is emerging as a new long-lasting and relatively safe analgesic.
Identifiants
pubmed: 32016565
doi: 10.1007/164_2019_348
doi:
Substances chimiques
Analgesics
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-264Références
Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28(14):3689–3696. https://doi.org/10.1523/JNEUROSCI.0375-08.2008
doi: 10.1523/JNEUROSCI.0375-08.2008
pubmed: 18385327
pmcid: 6671090
Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl 1):S9–S15. https://doi.org/10.1046/j.1526-4610.43.7s.3.x
doi: 10.1046/j.1526-4610.43.7s.3.x
pubmed: 12887389
Aoki KR (2015) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26(5):785–793. https://doi.org/10.1016/j.neuro.2005.01.017
doi: 10.1016/j.neuro.2005.01.017
Bach-Rojecky L, Lacković Z (2005) Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J 46(2):201–208
pubmed: 15849840
Bach-Rojecky L, Lacković Z (2009) Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 94(2):234–238. https://doi.org/10.1016/j.pbb.2009.08.012pain
doi: 10.1016/j.pbb.2009.08.012pain
pubmed: 19732788
Bach-Rojecky L, Relja M, Lacković Z (2005) Botulinum toxin type A in experimental neuropathic pain. J Neural Transm (Vienna) 112(2):215–219. https://doi.org/10.1007/s00702-004-0265-1
doi: 10.1007/s00702-004-0265-1
Bach-Rojecky L, Salković-Petrisić M, Lacković Z (2010) Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol 633(1–3):10–14. https://doi.org/10.1016/j.ejphar.2010.01.020
doi: 10.1016/j.ejphar.2010.01.020
pubmed: 20123097
Bomba-Warczak E, Vevea JD, Brittain JM, Figueroa-Bernier A, Tepp WH, Johnson EA, Yeh FL, Chapman ER (2016) Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons. Cell Rep 16:1974–1987. https://doi.org/10.1016/j.celrep.2016.06.104
doi: 10.1016/j.celrep.2016.06.104
pubmed: 27498860
pmcid: 4988880
Burstein R, Blake P, Schain A, Perry C (2017) Extracranial origin of headache. Curr Opin Neurol 30(3):263–271. https://doi.org/10.1097/WCO.0000000000000437
doi: 10.1097/WCO.0000000000000437
pubmed: 6051727
pmcid: 6051727
Caleo M, Spinelli M, Colosimo F, Matak I, Rossetto O, Lackovic Z, Restani L (2018) Transynaptic action of botulinum neurotoxin type A at central cholinergic boutons. J Neurosci 38(48):10329–10337. https://doi.org/10.1523/JNEUROSCI.0294-18.2018
doi: 10.1523/JNEUROSCI.0294-18.2018
pubmed: 30315128
pmcid: 6596210
Coelho A, Cruz F, Cruz CD, Avelino A (2012) Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 61(6):1178–1184. https://doi.org/10.1016/j.eururo.2012.01.046
doi: 10.1016/j.eururo.2012.01.046
pubmed: 22306320
Cruz F (2014) Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn 33(1):31–38. https://doi.org/10.1002/nau.22445
doi: 10.1002/nau.22445
pubmed: 23775898
Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107(1–2):125–133. https://doi.org/10.1016/j.pain.2003.10.008
doi: 10.1016/j.pain.2003.10.008
pubmed: 14715398
Diener H, Dodick DW, Aurora S, Turkel C, DeGryse R, Lipton R, Silberstein S, Brin M (2000) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–814. https://doi.org/10.1177/0333102410364677
doi: 10.1177/0333102410364677
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
doi: 10.1111/j.1526-4610.2010.01678.x
pubmed: 20487038
Drinovac Vlah V, Filipović B, Bach-Rojecky L, Lacković Z (2018) Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region. Eur J Pain 22(3):583–591. https://doi.org/10.1002/ejp.1146
doi: 10.1002/ejp.1146
pubmed: 29134730
Favre-Guilmard C, Auguet M, Chabrier PE (2009) Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 617(1–3):48–53. https://doi.org/10.1016/j.ejphar.2009.06.047
doi: 10.1016/j.ejphar.2009.06.047
pubmed: 19576881
Favre-Guilmard C, Chabrier PE, Kalinichev M (2017) Bilateral analgesic effects of abobotulinumtoxinA (Dysport®) following unilateral administration in the rat. Eur J Pain 21(5):927–937. https://doi.org/10.1002/ejp.995
doi: 10.1002/ejp.995
pubmed: 28263010
Filipović B, Matak I, Bach-Rojecky L, Lacković Z (2012) Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One 7(1):e29803. https://doi.org/10.1371/journal.pone.0029803.e29803
doi: 10.1371/journal.pone.0029803.e29803
pubmed: 22238656
pmcid: 3251614
Filipović B, Matak I, Lacković Z (2014) Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region. J Neural Transm (Vienna) 121(5):555–563. https://doi.org/10.1007/s00702-013-1144-4
doi: 10.1007/s00702-013-1144-4
Freund B, Schwartz M (2003) Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 4(3):159–165. https://doi.org/10.1054/jpai.2003.435
doi: 10.1054/jpai.2003.435
pubmed: 14622713
Habermann E (1974) 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedeberg’s Arch Pharmacol 281(1):47–56. https://doi.org/10.1007/bf00500611
doi: 10.1007/bf00500611
Ibragić S, Matak I, Dračić A, Smajlović A, Muminović M, Sofić E, Lacković Z, Riederer P (2016) Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats. Neurosci Lett 617:213–217. https://doi.org/10.1016/j.neulet.2016.02.020
doi: 10.1016/j.neulet.2016.02.020
pubmed: 26876447
Ji RR, Berta T, Nedergaard M (2013) Glia and pain: is chronic pain a gliopathy? Pain 154(Suppl 1):S10–S28. https://doi.org/10.1016/j.pain.2013.06.022
doi: 10.1016/j.pain.2013.06.022
pubmed: 23792284
pmcid: 3858488
Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma K (2009) Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159(4):1422–1429. https://doi.org/10.1016/j.neuroscience.2009.01.066
doi: 10.1016/j.neuroscience.2009.01.066
pubmed: 19409226
Koizumi H, Goto S, Okita S, Morigaki R, Akaike N, Torii Y, Harakawa T, Ginnaga A, Kaji R (2014) Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2. Front Neurol 5:98. https://doi.org/10.3389/fneur.2014.00098
doi: 10.3389/fneur.2014.00098
pubmed: 25002857
pmcid: 4066301
Kosaras B, Jakubowski M, Kainz V, Burstein R (2009) Sensory innervation of the calvarial bones of the mouse. J Comp Neurol 515(3):331–348
pubmed: 2710390
pmcid: 2710390
Lacković Z, Filipović B, Matak I, Helyes Z (2016) Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol 173(2):279–291. https://doi.org/10.1111/bph.13366
doi: 10.1111/bph.13366
pubmed: 26493010
Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly J (2012) Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem J 441:443–452. https://doi.org/10.1042/BJ20111117
doi: 10.1042/BJ20111117
pubmed: 21929507
Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly J (2013) Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP25. Neuropharmacology 70:287–295. https://doi.org/10.1016/j.neuropharm.2013.02.012
doi: 10.1016/j.neuropharm.2013.02.012
pubmed: 23485402
Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E, Caruso M, Straface E, Przewlocka B, Pavone F (2010) Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 171(1):316–328
doi: 10.1016/j.neuroscience.2010.08.067
Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AM, Luvisetto S, Pavone F (2012) The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One 7(10):e47977. https://doi.org/10.1371/journal.pone.0047977
doi: 10.1371/journal.pone.0047977
pubmed: 23110146
pmcid: 3480491
Matak I, Lacković Z (2015) Botulinum toxin A, brain and pain. Prog Neurobiol 119–120:39–59. https://doi.org/10.1016/j.pneurobio.2014.06.00
doi: 10.1016/j.pneurobio.2014.06.00
Matak I, Bach-Rojecky L, Filipović B, Lacković Z (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201–207. https://doi.org/10.1016/j.neuroscience.2011.04.026
doi: 10.1016/j.neuroscience.2011.04.026
pubmed: 21539899
Matak I, Riederer P, Lacković Z (2012) Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int 61(2):236–239. https://doi.org/10.1016/j.neuint.2012.05.001
doi: 10.1016/j.neuint.2012.05.001
pubmed: 22580329
Matak I, Rossetto O, Lacković Z (2014) Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 155(8):1516–1526. https://doi.org/10.1016/j.pain.2014.04.027
doi: 10.1016/j.pain.2014.04.027
pubmed: 24793910
Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z (2019) Mechanisms of botulinum toxin type A action on pain. Toxins (Basel) 11(8). pii: E459. https://doi.org/10.3390/toxins11080459
Michailov VV (1956) Bull Exp Biol Med. USSR 41, 45 (cit. by Tyler 1963)
Morris JL, König P, Shimizu T, Jobling P, Gibbins IL (2005) Most peptide-containing sensory neurons lack proteins for exocytotic release and vesicular transport of glutamate. J Comp Neurol 483(1):1–16. https://doi.org/10.1002/cne.20399
doi: 10.1002/cne.20399
pubmed: 15672399
Polley EH, Vick JA, Ciuchta HP, Fischetti DA, MacChitelli FJ, Montanarelli N (1965) Botulinum toxin, type A: effects on central nervous system. Science 147:1036–1037. https://doi.org/10.1126/science.147.3661.1036
doi: 10.1126/science.147.3661.1036
pubmed: 14245777
Radhakrishnan R, Moore SA, Sluka KA (2003) Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain 104(3):567–577. https://doi.org/10.1016/s0304-3959(03)00114-3
doi: 10.1016/s0304-3959(03)00114-3
pubmed: 12927629
pmcid: 2732018
Ramachandran R, Yaksh TL (2014) Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 171(18):4177–4192. https://doi.org/10.1111/bph.12763
doi: 10.1111/bph.12763
pubmed: 24819339
pmcid: 4241086
Rojewska E, Piotrowska A, Popiolek-Barczyk K, Mika J (2018) Botulinum toxin type A – a modulator of spinal neuron-glia interactions under neuropathic pain conditions. Toxins (Basel) 10(4). pii: E145. https://doi.org/10.3390/toxins10040145
Safarpour Y, Jabbari B (2018) Botulinum toxin treatment of pain syndromes – an evidence based review. Toxicon 147:120–128. https://doi.org/10.1016/j.toxicon.2018.01.017
doi: 10.1016/j.toxicon.2018.01.017
pubmed: 29409817
Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, Kuroi T, Ebine T, Koizumi K, Suzuki N (2012) Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 48(3):367–378. https://doi.org/10.1016/j.nbd.2012.07.010
doi: 10.1016/j.nbd.2012.07.010
pubmed: 22820141
Shinoda M, Kawashima K, Ozaki N, Asai H, Nagamine K, Sugiura Y (2007) P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain. J Pain 8:588–597
doi: 10.1016/j.jpain.2007.03.001
Sluka KA, Kalra A, Moore SA (2001) Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 24(1):37–46. https://doi.org/10.1002/1097-4598(200101)24:1<37::aid-mus4>3.0.co;2-8
doi: 10.1002/1097-4598(200101)24:1<37::aid-mus4>3.0.co;2-8
pubmed: 11150964
Stearns TP, Shad MU, Guzman GC (2018) Glabellar botulinum toxin injections in major depressive disorder: a critical review. Prim Care Companion CNS Disord 20(5). pii: 18r02298. https://doi.org/10.4088/PCC.18r02298
Tang-Liu DD, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF, Webber C (2003) Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42(5):461–469. https://doi.org/10.1016/s0041-0101(03)00196-x
doi: 10.1016/s0041-0101(03)00196-x
pubmed: 14529727
Tracey I, Bushnell MC (2009) How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain 10:1113–1120. https://doi.org/10.1016/j.jpain.2009.09.001
doi: 10.1016/j.jpain.2009.09.001
pubmed: 19878862
Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12(4):314–316. https://doi.org/10.1017/s031716710003540x
doi: 10.1017/s031716710003540x
pubmed: 4084867
Tyler HR (1963) Botulinus toxin: effect on the central nervous system of man. Science 139:847–848. https://doi.org/10.1126/science.139.3557.847
Vacca V, Marinelli S, Eleuteri C, Luvisetto S, Pavone F (2012) Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. Brain Behav Immun 26(3):489–499. https://doi.org/10.1016/j.bbi.2012.01.002
doi: 10.1016/j.bbi.2012.01.002
pubmed: 22281280
Wiegand H, Erdmann G, Wellhöner HH (1976) 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedeberg’s Arch Pharmacol 292:161–165. https://doi.org/10.1007/bf00498587
doi: 10.1007/bf00498587